DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
申请人:Rafferty Michael
公开号:US20120059008A1
公开(公告)日:2012-03-08
The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.
Mass spectrometry in structural and stereochemical problems. CLXXX. Oxygen rearrangement and fragmentation reactions after electron impact on 4-hydroxy- and 4-alkoxy-1-decalones
作者:Robin T. Gray、Masazumi Ikeda、Carl Djerassi
DOI:10.1021/jo01264a072
日期:1969.12
JPS61204178A
申请人:——
公开号:JPS61204178A
公开(公告)日:1986-09-10
Selective catalytic hydrogenation of polycyclic aromatic hydrocarbons promoted by ruthenium nanoparticles
for hydrogenation of polycyclicaromatichydrocarbons (PAHs) containing 2–4 rings undermild reaction conditions. These compounds were partially hydrogenated with good to excellent selectivities just by optimizing the reaction conditions. The influence of the nature of substituents present in different positions of naphthalene on the selectivity of hydrogenation was also studied. Hydrogenation of products